Issues in the treatment of active tuberculosis in human immunodeficiency virus-infected patients. NLM AIDSLINE Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Issues in the treatment of active tuberculosis in human immunodeficiency virus-infected patients.

Clin Infect Dis. 1999 Jan;28(1):130-5. Unique Identifier : AIDSLINE MED/99152409
Schluger NW; Division of Pulmonary, Allergy, and Critical Care Medicine,; Columbia University College of Physicians and Surgeons, New York,; New York 10032, USA. ns311@columbia.edu

Abstract: Most HIV-infected patients with tuberculosis can be treated satisfactorily with standard regimens with expectations of good results. Treatment of tuberculosis in these patients has been complicated by the introduction of HAART, which relies on drugs that interfere with the most potent class of antituberculous medications. Rifampin-free regimens or regimens that employ rifabutin may be acceptable strategies for patients who are receiving protease inhibitors, although these regimens have not been rigorously evaluated in patients with AIDS. At present, there is good reason to believe that a 6-month course of a rifabutin-containing regimen or a 9-12-month course of a regimen of streptomycin, isoniazid, and pyrazinamide should be adequate therapy for most patients with drug-susceptible disease. As the treatment of HIV infection with antiretroviral agents evolves, the treatment of tuberculosis in patients with AIDS is likely to evolve as well. This will require careful coordination of antituberculosis and antiretroviral therapies.
Keywords: JOURNAL ARTICLE REVIEW REVIEW, TUTORIAL Adjuvants, Immunologic/THERAPEUTIC USE Anti-HIV Agents/*THERAPEUTIC USE Antitubercular Agents/*THERAPEUTIC USE AIDS-Related Opportunistic Infections/*DRUG THERAPY/MICROBIOLOGY Clinical Trials Drug Interactions Human HIV Protease Inhibitors/*THERAPEUTIC USE Rifamycins/THERAPEUTIC USE Tuberculosis/*DRUG THERAPY Tuberculosis, Multidrug-Resistant/DRUG THERAPYKWDjournalarticlereviewreview,tutorialadjuvants,immunologic/therapeuticuseanti-hivagents/KWDtherapeuticuseantitubercularagents/KWDtherapeuticuseaids-relatedopportunisticinfections/KWDdrugtherapy/microbiologyclinicaltrialsdruginteractionshumanhivproteaseinhibitors/KWDtherapeuticuserifamycins/therapeuticusetuberculosis/KWDdrugtherapytuberculosis,multidrug-resistant/drugtherapy
990930
A9991304

Copyright © 1999 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .